Immunomodulation and therapeutic effects of the oral use of interferon- α: Mechanism of action

Journal of Interferon and Cytokine Research

Volumn 19, Issue 8, 1999, Pages 817-828

  Tompkins, Wayne A ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; CYTOKINE; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 RECEPTOR; INTERLEUKIN 4; RECOMBINANT INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 5; RECOMBINANT INTERLEUKIN 6;

ASTHMA; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DRUG MECHANISM; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; SJOEGREN SYNDROME; VIRUS INFECTION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INTERFERON-ALPHA; MUCOUS MEMBRANE;

CYTOMEGALOVIRUS;

EID: 0032818247     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/107999099313325     Document Type: Review

References (69)

1. AHMED, R. (1996). Tickling memory T cells. Science 272, 1904.
2. TOUGH. D.F., BORROW. P., and SPRENT, J. (1996). Induction of bystander T cell proliferation by viruses and Type I interferon in vivo. Science 272, 1947-1950.
3. MULLER, U., STEINHOFF, U., REIS, L.F., HEMMI, S., PAVLOVIC, J., ZINKERHAGEL, R.M., and AGUET, M. (1994). Functional role of Type I and Type II interferons in antiviral defense. Science 264, 1918-1921.
4. BEILHARZ, M.W., McDONALD, W., WATSON, M.W., HENG, J., McGEACHIE, J., and LAWSON, C.M. (1997). Low-dose oral Type 1 interferons reduce early virus replication of murine cytomegalovirus in vivo. J. Interferon Cytokine Res. 17, 625-630.
5. CUMMINS, J.M., HUTCHESON, O.P., GEORGIADES, J.A., and RICHARDS, A.B. (1993). Oral therapy with human interferon alpha in calves experimentally injected with infectious bovine rhinotracheitis virus. Arch. Immunol. Ther. Exp. 41, 193-198.
6. GEORGIADES, J.A. (1993). Effect of low dose natural human interferon alpha given into the oral cavity on the recovery time and death loss in feedlot hospital pen cattle: a field study (short communication). Arch. Immunol. Ther. Exp. 41, 205-208.
7. YOUNG, A.S., MARITIM, A.C., KARIUKI, D.P., STAGG, D.A., WAFULA, J.M., MUTIGI, J.J., CUMMINS, I.M., RICHARDS, A.B., and BURNS, C. (1990). Low dose oral administration of human interferon alpha in cattle. Parasitology 101, 201-209.
8. CUMMINS, J.M., GAWTHROP, J., HUTCHESON, D.P., CUMMINS, M.J., and ZECK, D. (I993). The effect of low-dose oral human interferon alpha therapy on diarrhea in veal calves. Arch. Immunol. Ther. Exp. 41, 199-204.
9. MOORE, B.R., KRAKOWKA, S., CUMMINS, J.M., and ROBERTSON, J.T. (1996). Changes in airway inflammatory cell populations in standardised racehorses after imerferon-alpha administration. Vet. Immunol. Immunopathol. 49, 347-358.
10. CUMMINS, J.M., MOCK, R.E., SHIVE, B.W., KRAKOWKA, S., RICHARDS, A.B., and HUTCHESON, D.P. (1995), Oral treatment of transmissible gastroenteritis with natural human interferon alpha: A field study. Vet. Immunol. Immunopathol. 45, 355-360.
11. LECCE, J.G., CUMMINS, J.M., and RICHARDS, A.B. (1990). Treatment of rotavirus infection in neonate and weanling pigs using natural human interferon alpha. J. Mol. Biotherapy 2, 211-216.
12. CABAN, J., MOSSOR-OSTROWSKA, J., ZYRKOWSKA-BIEDA, T., ZEJC, M., JANAS-SKULINA, U., CIESLA, A., CUMMINS, J.M., and GEORGIADES, J.A. (1993). Treatment of chronic viral hepatitis type B with oral mucosal administration of natural human interferon alpha lozenges. Arch. Immunol. Ther. Exp. 41, 229-235.
13. ZIELINSKA, W., PASZKIEWICZ, J., KORCZAK, A., WLASIUK, M., ZOLTOWSKA, A., SZUTPWICZ, A., CUMMINS, J.M., and GEORGIADES, J.A. 0993). Treatment of six patients with chronic active HCV hepatitis, with low dose natural human interferon alpha administered orally. Arch. Immunol. Ther. Exp. 41, 253-257.
14. WEISS, R.C., CUMMINS, J.M., and RICHARDS, A.B. (1991). Low-dose orally administered alpha interferon treatment for feline leukemia virus infection. J. Am. Vet. Med. Assoc. 199, 1477-1481.
15. TOVEY, M.G., and MAURY, C. (1999). Oral mucosal interferon therapy: Marked antiviral and antitumor activity. J. Interferon Cytokine Res. 19, 145-155.
16. ERICSSON, A.D., and ENGLE, A.C. III. (1991). Clinical studies phase II: polymyositis. Raum Zeit 2, 10-14.
17. BROD, S.A., KERMAN, R.H., NELSON, L.D., MARSHALL, G.D. Jr., HENNINGER, E.M., KHAN, M., JIN, R., and WOLINSKY, J.S. (1997). Ingested IFN-alpha has biological effects in humans with relapsing-remitting multiple sclerosis. Mult. Scler. 3, 1-7.
18. SHIOZAWA, S., TANAKA, Y., and SHIOZAWA, K. (1998). Single-blinded controlled trial of low-dose oral IFN-α for the treatment of xerostomia in patients with Sjögren's Syndrome. J. Interferon Cytokine Res. 18, 255-262.
19. BROD, S.A., SCOTT, M., BURNS, D.K., and PHILLIPS, J.T. (1995). Modification of acute experimental autoimmune encephalomyelitis in the Lewis rat by oral administration of Type 1 interferons. J. Interferon Cytokine Res. 15, 115-122.
20. BROD, S.A., and BURNS, D.K. (1994). Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of Type I Interferons. Neurol. 44, 1144-1148.
21. BROD, S.A. (1997). Effects of oral administration of Type I interferon on experimental autoimmune encephalomyelitis. In: Interferon Therapy of Multiple Sclerosis. A.T. Reder (ed.) New York: Marcel Dekker, pp. 245-286.
22. NELSON, P.A., ALSELBAND, Y., DEARBORN, S.M., AL-SABBAGH. A., TIAN, Z.J., GONNELLA, P.A., ZAMVIL, S.S., CHEN, Y., and WEINER, H.L. (1995). Effect of oral beta interferon on subsequent immune responsiveness. Ann. N.Y. Acad. Sci. 778, 145-55.
23. FLEISCHMANN, W.R. Jr., FIELDS, E.E., WANG, J.L., HUGHES, T.K., and STANTON, G.J. (1991). Modulation of peripheral leukocyte counts in mice by oral administration of interferon. Proc. Soc. Exp. Biol. & Med. 197, 424-430.
24. FLEISCHMANN, W.R., JR., KOREN, S., and FLEISCHMANN, C.M. (1992). Orally administered interferon exert their while blood cell suppression effects via a novel mechanism. Proc. Soc. Exp. Biol. & Med. 201, 199-207.
25. SHANLEY, T.P., WARNER, R.L., WARD, P.A., and CUMMINS, J. (1996). ''Oral human interferon-α modulates acute lung injury in rats." Unpublished. University of Michigan. Ann Arbor, Michigan.
26. SALAZAR-MATHER, T.P., ISHIKAWA, R., and BIRON, C.A. (1996). NK cell trafficking and cytokine expression in splenic compartments after IFN induction and viral infection. J. Immunol. 157, 3054-3064.
27. SOOS, J.M., MUJTABA, M.G., SLBRAMANIAM, P.S., STREIT, W.J., and JOHNSON, H.M. (1997). Oral feeding of interferon τ can prevent the acute and chronic relapsing forms of experimental allergic encephalomyelitis. J. Neuroimmunol. 75, 43-50.
28. YOSHINO, S. (1996). Effects of oral administration of Type I interferon on adjuvant arthritis in rats. Comp. Immunol. Microbiol. Infect. Dis. 19, 133-138.
29. HAVELL, E.A., and SPITAL, N.Y. (1983). Endotoxin-induced interferon synthesis in macrophage cultures. J. Reticuloendothelial Soc. 33, 369-380.
30. KHOURY, S.J., HANCOCK, W.W., and WEINER, H.L. (1992). Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with down-regulation of inflammatory cytokines and differential upregulation of TGF-β, IL-4 and PGE expression in the brain. J. Exp. Med. 46, 1355-1364.
31. TAKAYAMA, S., IWAKI, K., NISHIDA, Y., TANAKA, M., FUJII. M., OHASHI, K., IKEDA, M., and KURIMOTO, M. (1997). Effects of oral-mucosal IFN-α on antibody production in mice with induced tolerance. J. Interferon Cytokine Res. 17, S62.
32. SATOH, Y., KYOKO, K., SATO, M., KUWABARA, M., and YANAI, A. (1997). Induction of tissue 2′5′AS and suppression of delayed type of asthma reaction by oral administration of IFN-β in guinea pig asthma model. J. Interferon Cytokine Res. 17, S96.
33. TANAKA-KATAOKA, M., KUNIKATA, T., TAKAYAMA, S., IWAKI, K., FUJII, M., OHASHI, K., IKEDA, M., and KURIMOTO, M. (1999). Oral use of interferon-α delays the onset of insulin-dependent diabetes mellitus in nonobese diabetes mice. J. Interferon Cytokine Res. 19, 877-879.
34. EVERSON, M.P., LEMAK, D.G., McDUFFIE, D.S., KOOPMAN, W.J., McGHEE, J.R., and BEAGLEY, K. W. (1998). Dendritic cells from Peyer's patch and spleen induce different T helper cell responses. J. Interferon Cytokine Res. 18, 103-115.
35. MARINARO, M., BOYAKA, P.N., RINKELMAN, F.D., KIYONO, H., JACKSON, R.J., JIRILLO, E., and McGHEE, J.R. (1997). Oral but not parenteral interleukin (IL)-12 redirects T helper 2 (Th2)-type responses to an oral vaccine without altering mucosal IgA responses. J. Exp. Med. 185, 415-421.
36. BAQAR, S., PACHECO, N., and ROLLWAGEN, F.L. (1993). Modulation of mucosal immunity against Campylobacter jejuni by orally administered cytokines. Antimicrobial Agents Chemotherapy 37, 2688-2692.
37. HENDRZAK, J., and BRUNDA, M. (1995). Biology of disease: interleukin-12, biologic activity, therapeutic utility and role in disease. Lab. Investig. 72, 619-639.
38. KOBAYASHI, M., FITZ, L., RYAN, M., HEWICK, R.M., CLARK, S.C., CHAN, S., LOUDON, R., SHERMAN, F., PERUSSIA, B., and TRINCHIERI, G. (1989). Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170, 827.
39. FINKLEMAN, F.D., KATONA. I.M., MORSMANN, T.R., and COFFMAN, R.L. (1988). IFN-γyregulates the isotype of Ig secreted furing in vivo humoral immune response. J. Immunol. 140, 1022-1027.
40. + blood dendritic cells are potent producers of IFN-α in response to in vitro HIV-1 infection. J. Immunol. 152, 4649-4662.
41. TOVEY, M.G., BENIZRI, E., GUGENHEIM. J., BERNARD, G., EID, P., BLANCHARD, B., and HOFMAN, P. (1996). Role of the Type I interferons in allograft rejection. J. Leukocyte Biol. 59, 512-517.
42. PENE, J., ROUSSET, F., BRIER, F., CHRETIEN, I., BONNEFOY, J.Y., SPITS, H., YOKOTA, T., ARAI, N., BENCHEREAU, J. and VRIES, J. (1988). IgE production by normal human lymphocytes is induced by IL4 and suppressed by IFNγ and α and prostaglandin E. Proc. Natl. Acad. Sci. USA 85, 6880-6884.
43. FINKLEMAN. F.D., SVETIC, A., GRESSOR, I., SNAPPER, C, HOLMES, J., TROTTA, P., KATONA, I., and GAUSE, W. (1991). Regulation by Interferon α of immunoglobulin isotype selection and lymphokine production in mice. J. Exp. Med. 174, 1179-1188.
44. TONKONOGY, S. (1994). Effect of intranasal administration of interferon-α on lymphoid cell phenotype and function. Presented at the Annual Meeting of the International Society for Interferon Research in Budapest, Hungary.
45. PARRONCHI, P., De CARLI, M., MANETTI, R., SIMONELLI, C., SAMPOGNARO, S., PICCINNI, M.P., MACCHIA, D., MAGGI, E., DEL PRETE, G., and ROMAGNANI, S. (1992). IL4 and IFN (α and γ) exert opposite regulatory effects on the development of cytolytic potential by Th 1 or Th2 human T cell clones. J. Immunol. 149, 2977-2983.
46. GOBL, A.E., and ALM, G.V. (1992). Interleukin-4 down regulates sendai virus-induced production of interferon-alpha and -beta in human peripheral blood monocytes in vitro. Scand. J. Immunol. 35, 167-175.
47. BRINKMAN, V., HEUSSER, C.H., BAER, J., KILCHHERR, E., and ERARD, F. (1993). Interferon-α suppresses the capacity of T cells to help antibody production by human B cells. J. Exp. Med. 178, 1655-1663.
48. KONISHI, K., TANABE, F., TANIGUCHI, M., YAMAUCHI, H., TANIMOTO, T., IKEDA, M., ORITA, K., and KURIMOTO, M. (1997). A simple and sensitive bioassay for the detection of human interleukin-18/interferon-gamma-inducing factor using human myelomonocytic KG-1 cells. J. Immunol. Methods 209, 187-191.
49. HENG, J.K., PRICE, P., LAI, C.M., and BEILHARZ, M.W. (1996). Alpha/Beta interferon increase resistance to murine AIDS. J. Virol. 70, 4517-4522.
50. KOS, F.J., and ENGLEMAN, E.G. (1996). Requirement for natural killer cells in the induction of cytotoxic T cells. J. Immunol. 154, 578-584.
51. KYBURZ, D., AICHELE, P., SPEISER, D.E., HENGARTNER, H., ZINKERNAGEL, R.M., and PIRCHER, H. (1996). T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides. Eur. J. Immunol. 23, 1956-1962.
52. ROGGE, L., BARBERIS-MAINO, L., BIFFI, M., PASSINI, N., PRESKY, D.H., GUBLER, U., and SINIGAGLIA, F. (I997). Selective expression of an interleukin-12 receptor components by human T helper 1 cells. J. Exp. Med. 185, 825-831.
53. CHO, S.S., BACON, CM., SUDARSHAN, C., REES, R.C., FINBLOOM, D., PINE, R., and O'SHEA, J.J. (1996). Activation for the involvement of ligand-induced tyrosine and serine phosphorylation. J. Immunol. 157, 4781-4789.
54. SZABO, S.J., DIGHE, A.S., GUBLER, U., and MURPHY, K.M. (1997). Regulation of the interleukin (IL)-12Rβ2 subunit expression in developing T helper 1 (Th1) and Th2 cells. J. Exp. Med. 185, 817-824.
55. D'CUHNA, J., KNIGHT, E., JR., HAAS, A.L., TRUITT, R.L., and BORDEN, E.C. (1996). Immunoregulalory properties of ISG15, an interferon-induced cytokine. Immunol. 93, 211-215.
56. FLESCH, I.E., HESS, J.H., HUANG, S., AGUET, M., ROTHE, J., BLUETHMANN, H., and KAUFMANN, S.H. (1995). Early interfeukin 12 production by macrophages in response to mycobac- terial infection depends on interferon gamma and tumor necrosis factor alpha. J. Exp. Med. 181, 1615-1621.
57. SMITH, J.K., SIDDIQUI, A.A., KRISHNASWAMY, G.A., DYKES, R., BERK, S.L., MAGEE, M., and CUMMINS, J. Oral interferon-alpha stimulates ISG-15 transcription and production by human buccal epithelial cells. J. Interferon Cytokine Res. 19, 000-000.
58. OKAMURA, H., TSUTSI, H., KIMATSU, T., YUTSUDO, M., HAKURA, A., TANIMOTO, T., TORIGOE, K., OKURA, T., NUKADA, Y., AND HATTORI, K, et al. (1995). Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 378, 88-91.
59. DeMAEYER, E. (1984). Interferons and the immune system. In: Interferon, Volume 1: General and Applied Aspects. A. Billiau (ed.) Amsterdam: Elsevier, pp. 168-185.
60. ISAACS, A., BURKE, D.C., and FADEEVA, L. (1958). Effect of interferon on the growth of viruses on the chick chorion. Br. J. Exp. Path. 39, 447-451.
61. LOCKHART, R.Z., JR. (1963). Production of an interferon by L cells infected with WEE virus, J. Bacteriol. 85, 556-566.
62. STEWART, W.E. (1979). In: The Interferon System. Vienna and New York: Springer-Verlag, pp. 233-239.
63. HAVELL, E.A. (1993). Listeria monocytogenes-induced interferon-γ primes the host for production of tumor necrosis factor and interferon-α/β. J. Infect. Dis. 167, 1364-1371.
64. ORANGE, J.S., WOLF, S.F., and BIRON, C.A. (1993). Effects of IL-12 on the response and susceptibility to experimental viral infections. J. Immunol. 151, 1252-1264.
65. PRETNAR, P., STEINDL, F., MEAGER, A., THORPE, R., BORTH, N., SCHMATZ, C, METZGER, R., KATINGER, H.W.D., and FERLAN, I. (1998). Interferon α primes early pro- liferative response of bone marrow cells in vivo. Cytokine 10, 185-191.
66. + T lymphocytes: influence of IFN-α and interleukin-4. J. Interferon Cytokine Res. 18, 95-102.
67. LACK, G., BRADLEY, K.L., HAMELMANN, E., RENZ, H., LOADER, J., LEUNG, D.Y.M., LARSEN, G., and GELFAND, E.W. (1996). Nebulization IFN-γ inhibits the development of secondary allergic responses in mice. J. Immunol. 157, 1432-1439.
68. DUBRAVEC, D.B., SPRIGGS, D.R., MANNICK, J.A., and RODRICK, M.C. (1990). Circulating human peripheral blood granulocytes synthesize and secrete tumor necrosis factor a. Proc. Natl. Acad. Sci. USA 87, 6758-6761.
69. BELARDELLI, F., and GRESSER, I. (1996). The neglected role of Type 1 interferon in the T-cell response: implications for its clinical use. Immunol. Today 17, 369-372.